Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Clinical trial NCT05396885 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05396885
- Sponsor
- Kite, A Gilead Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-15
- Primary completion
- 2026-12-01
- Enrollment
- 136
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.